Advancing Mechanism-Based Therapies in
Neuroinflammation
About us
AndzonBio2 develops early-stage therapies focused on neuroinflammation, a key driver of
neurological and neurodegenerative diseases.
Advancing novel mechanisms with strong therapeutic potential
Cutting-edge academic science
Rigorous translational development
Strategic partnerships
Our vision
Enable the development of innovative, mechanism-based therapies addressing the root causes of neurological disorders for underserved patients.
Our focus
Neuroinflammation is increasingly recognized as a disease driver, not just as a downstream consequence.
By focusing on this biology, we aim to build differentiated, disease-modifying therapies
for patients living with brain disorders where treatment options remain limited.
Indication agility
Differenciated therapeutic profiles
Partnering flexibility across the development
collaboration
Partnering with Visionaries
We welcome discussions with pharma, biotech, academic groups
and investors who share our vision in neuroinflammation.
latest updates
News & Events
-
AndzonBio2, the ALBORADA Drug Discovery Institute at the University of Cambridge and Cambridge Enterprise Announce a Collaboration to Develop First-in-Class Therapeutics for Neuroinflammation
-
Join AndzonBio2 team at BioEurope in Lisbon
-
AndzonBio2 Strengthens Scientific and Strategic Capabilities with New Advisory Board and Leadership Appointment.
-
AndzonBio2 emerges from stealth mode and announces initial €3M seed fundingto advance breakthrough treatments for neurological disorders.